Research business

Biopharmaceutical Contract Manufacturing Market Research 2022 – Impact of COVID-19 and Global Analysis by Downstream, Upstream, Fill & Finish, Analytical & Quality Control, Packaging –

DUBLIN–(BUSINESS WIRE)–The “Biopharmaceutical Contract Manufacturing Market Forecast to 2028 – Impact of COVID-19 and Global Analysis by Product; Service, Source and Geography” report has been added to from offer.

The Biopharmaceutical Contract Manufacturing Market is expected to reach US$27,868.50 million by 2028 from US$15,735.04 million in 2021; it is expected to grow at a CAGR of 8.5% from 2021 to 2028.

The increasing outsourcing by pharmaceutical companies is one of the major factors driving the market growth. A few years ago, the contract manufacturing industry was a niche service market providing additional manufacturing capacity or specific services to pharmaceutical companies.

The rise of CMOs has been fueled by the growing number of drug manufacturing failures. In the past, pharmaceutical companies had undertaken manufacturing facilities to develop innovative drugs. However, to reduce the risk of overcapacity, the demand for manufacturing outsourcing has steadily increased.

Recently, Revolo Biotherapeutics entered into a partnership with Contract Development and Manufacturing Organization (CDMO) – Northway Biotech – to manufacture Revolo’s immunoregulatory binding protein 1805. The partnership included services ranging from cell line development to protein manufacturing with quality assurance and regulatory compliance assistance. Similarly, Gland Pharma has been manufacturing Remdesivir for four companies, including Mylan, since 2021.

Additionally, the organization has increased its manufacturing quotas due to strong corporate demand. In 2019, Samsung Biologics and GI Innovation signed an immunochemotherapy contract. Under the agreement, Samsung Biologics provided services ranging from the development of f-cell lines to the production of phase I drug substances.

The increasing number of contracts between biopharmaceutical companies and contract manufacturing companies shows an increasing market size for the biopharmaceutical contract manufacturing market.

On the basis of product, the market is segmented into biologics and biosimilars. The organic products segment would account for the largest market share during the period 2021-2028. Biologics is expected to experience robust growth due to various products in the segment, such as monoclonal antibodies, recombinant proteins, vaccines and others.

Biologics have a growing demand with increasing research and development activities to develop new drug products for chronic indications. The COVID-19 pandemic is also expected to drive the growth of the biologics segment as demand for vaccines against the virus increases. Also, monoclonal antibodies are needed for various chronic diseases of metabolic, infectious, neurological and other origin.

By service, the biopharmaceutical contract management market is segmented into process development, fill and finish operations, analytical and quality control studies, and packaging. The process development segment is expected to hold the largest market share during the forecast period owing to the highest investments in process development for the production of any biopharmaceutical.

The focus on commercial scale pilot process development, cell line development and other processes is expected to create growth opportunities for the process development segment. The segment is further divided into downstream and upstream processing, with the downstream processing holding the largest share as the downstream processing involves a larger amount of products under development. The analytical and quality control studies segment is expected to witness the highest growth rate.

By source, the biopharmaceutical contract management market is segmented into mammalian and microbial/non-mammalian biologics.

The mammalian segment is expected to hold a larger share of the market, as mammalian cell sources are more commonly used in industry and can develop a wider range of products compared to microbial-based biologics/non-mammalian sources.

Main topics covered:

1. Introduction

2. Biopharmaceutical Contract Manufacturing Market – Key Takeaways

3. Research methodology

4. Biopharmaceutical Contract Manufacturing – Market Landscape

4.1 Overview

4.2 PEST analysis

4.3 Expert opinion

5. Contract manufacturing of biopharmaceuticals market – key market dynamics

5.1 Market Drivers

5.1.1 Increase in outsourcing by pharmaceutical companies

5.1.2 Increase in demand for organic products

5.2 Market Constraints

5.2.1 Growing Competition in the Industry

5.3 Market Opportunities

5.3.1 Emerging markets

5.4 Future trends

5.4.1 Consolidation in CMO Pharmaceutical Industry

5.4.2 COVID-19 pandemic

5.5 Impact analysis

6. Biopharmaceutical Contract Manufacturing Market – Global Analysis

6.1 Global Biopharmaceutical Contract Manufacturing Market Revenue Forecast and Analysis

6.2 Global Biopharmaceutical Contract Manufacturing Market, by Geography – Forecast and Analysis

6.3 Market Positioning of Key Players

7. Contract Manufacturing of Biopharmaceuticals Market Analysis – By Product

7.1 Overview

7.2 Biopharmaceutical Contract Manufacturing Market Revenue Share, by Product (2021 and 2028)

7.3 Biological products

7.3.1 Preview

7.3.2 Biologics: Biopharmaceuticals Contract Manufacturing Market – Revenue and Forecast to 2028 (USD Million) Monoclonal antibodies Recombinant proteins Vaccines Others

7.4 Biosimilar

8. Contract Manufacturing of Biopharmaceuticals Market – By Service

8.1 Overview

8.2 Contract Manufacturing of Biopharmaceuticals Market, by Service, 2021 & 2028 (%)

8.3 Process development

8.3.1 Preview

8.3.2 Process Development: Biopharmaceuticals Contract Manufacturing Market – Revenue and Forecast to 2028 (USD Million) Downstream processing Upstream processing

8.4 Filling and finishing operations

8.5 Analytical and Quality Control Studies

8.6 Packaging

9. Contract Manufacturing of Biopharmaceuticals Market – By Source

9.1 Overview

9.2 Contract Manufacturing of Biopharmaceuticals Market, by Source, 2021 & 2028 (%)

9.3 Biological products of mammalian origin

9.3.1 Preview

9.3.2 Mammalian-based Biologics: Biopharmaceuticals Contract Manufacturing Market – Revenue and Forecast to 2028 (USD Million)

9.4 Microbial/non-mammalian biologicals

10. Biopharmaceutical Contract Manufacturing Market – Geographical Analysis

11. Impact of COVID-19 Pandemic on the Biopharmaceutical Contract Manufacturing Market

12. Biopharmaceutical Contract Manufacturing Market – Industry Landscape

12.1 Overview

12.2 Growth Strategies Performed by Market Companies, (%)

12.3 Organic developments

12.4 Inorganic developments

13. Business Profiles

  • Lonza S.A.

  • Boehringer Ingelheim Biopharmaceuticals GmbH

  • Inno Bio Ventures Sdn Bhd

  • ThermoFisher Scientific, Inc.

  • AbbVie, Inc.

  • WuXi Biologics, Inc.

  • General Electricity Company.

  • Samsung Biologics Co.Ltd.

  • Merck KGaA

  • Ajinomoto Co. Inc.

For more information on this report, visit